As IDSA News went to press, legislation that includes incentives to spur new antibiotic research and development was nearing passage in Congress. IDSA voiced its support for provisions in the Food and Drug Administration Prescription Drug User Fee Act (PDUFA) reauthorization bill in letters earlier this month to Senate (PDF) and House (PDF) committees. IDSA also offered additional proposals for consideration, including the Society’s proposed Limited Population Antibacterial Drug (LPAD) pathway, which would provide an important new approval option for companies interested in developing drugs for serious resistant infections with few or no existing treatment options.
IDSA continues to work on many fronts to address the anemic antibacterial pipeline. A recently launched IDSA webpage, www.AntibioticsNow.org, centers on patients affected by resistant infections and provides an easy way for concerned physicians to urge Congress to act. Visit IDSA’s “Take Action” webpage to send messages to your representatives in Congress on this issue and urge your colleagues to do the same. Members can also help IDSA identify patients and families who are willing to share their experiences with the media, policymakers, and the public. (Several stories are featured on IDSA’s website. Contact IDSA staff for more information.)
< Previous Article | Next Article >